The Experts below are selected from a list of 12873 Experts worldwide ranked by ideXlab platform

C La Vecchia - One of the best experts on this subject based on the ideXlab platform.

  • Hormone Replacement Treatment and breast cancer risk an age specific analysis
    Cancer Epidemiology Biomarkers & Prevention, 1997
    Co-Authors: Alessandra Tavani, Claudia Braga, C La Vecchia, Eva Negri, Silvia Franceschi
    Abstract:

    The relationship between Hormone Replacement Treatment (HRT) and breast cancer risk was considered in age-specific groups of women, combining data from two case-control studies conducted between 1983 and 1994 in six Italian centers. Cases were comprised of 5984 women, below age 75 years, with histologically confirmed breast cancer, and controls were comprised of 5504 women admitted to the hospital for a wide spectrum of acute, nonneoplastic, nonHormone-related diseases. Ever-use of HRT was reported by 6.1% of the cases and 5.5% of the controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95% confidence interval (CI), 1.0-1.4]. A significant trend in risk with duration of use was observed. Separate analysis for women or = 60 months of use. Thus, this study suggests that the relationship between HRT and breast cancer risk is influenced by age at diagnosis and that any risk-benefit assessment is particularly critical for women using HRT several years after menopause.

  • oral contraceptives menopausal Hormone Replacement Treatment and breast cancer risk
    European Journal of Cancer Prevention, 1996
    Co-Authors: F Levi, F Lucchini, C Pasche, C La Vecchia
    Abstract:

    The relationship between oral contraceptives (OC), menopausal Hormone Replacement Treatment (HRT) and breast cancer risk was analysed in a case-control study conducted in the Swiss canton of Vaud on 230 cases below the age of 75, linked with the Vaud cancer registry, and 507 controls in hospital for a wide spectrum of acute, non-neoplastic, non-Hormone-related diseases. A total of 77 (37.4%) cases and 134 (31.6%) of controls below the age of 70 had ever used OC, corresponding to a multivariate odds ratio (OR) of 1.5, of borderline significance. The risk was related to duration of use, but this might be partly due to a recency effect. In fact, with reference to time since last OC use, the OR was above unity for up to 14 years, but declined to 1.0 for women who had stopped OC use for ≥ 15 years. With reference to HRT, ever users were 64 (27.8%) of cases and 113 (23.3%) of controls, yielding a multivariate OR of 1.3. Also, for HRT the association was stronger for shorter time since last use ; the OR was 1.5 for women who had stopped for <10 years, but declined to 0.8 for those who had stopped for 10 years or longer. The association with HRT was stronger for women aged ≥ 65. Thus, the present study confirms that breast cancer risk is moderately related to OC and HRT. The association, however, is essentially restricted to the 10-15 years after stopping use. This pattern of risk is consistent with a late-stage effect of steroid Hormone preparations on the process of breast carcinogenesis, and has relevant implications for any risk/benefit assessment and public health evaluation.

  • Hormone Replacement Treatment and breast cancer risk a cooperative italian study
    British Journal of Cancer, 1995
    Co-Authors: C La Vecchia, Eva Negri, Silvia Franceschi, A Favero, Oriana Nanni, Rosa Filiberti, E Conti, Maurizio Montella, A Veronesi, Monica Ferraroni
    Abstract:

    The relationship between Hormone Replacement Treatment (HRT) and breast cancer risk was analysed using data from a case-control study conducted between June 1991 and February 1994 in six Italian centres on 2569 patients aged below 75 with histologically confirmed breast cancer and 2588 controls admitted to hospital for a wide spectrum of acute, non-neoplastic, non Hormone-related diseases. Ever HRT use was reported by 7.5% of cases and 7.5% of controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95% confidence interval (CI), 0.9-1.5]. The risk increased with increasing duration of use: the ORs were 1.0 for use lasting less than 1 year, 1.3 for 1-4 years and 1.5 for 5 years or more. There was no clear pattern of risk with reference to time since starting use, but the OR was significantly elevated (OR = 2.0, 95% CI 1.3-2.9) for women who had stopped HRT within the last 10 years. No association was observed in those who had stopped HRT more than 10 years ago (OR = 1.0). The increased OR for women who had stopped HRT within the last 10 years was consistent across strata of identified covariates, and was significantly related to duration of use. This study confirms the absence of a strong association between HRT and breast cancer risk, although the risk estimate was above unity for women who had used HRT for 5 years or longer. However, the risk was significantly elevated in the short to medium term after use, particularly for long-term use. This short-term increased risk is consistent with an effect of HRT on one of the later stages of the process of breast carcinogenesis. The flattening of risk with increasing time since stopping, and hence the absence of a long-term cumulative excess in breast cancer risk after stopping HRT exposure, has relevant implications on individual risk assessment and public health.

C Zhou - One of the best experts on this subject based on the ideXlab platform.

  • 8 comparison of natural cycles versus Hormone Replacement Treatment for 2398 frozen thawed embryo transfer cycles for preimplantation genetic testing patients
    Reproductive Biomedicine Online, 2019
    Co-Authors: Xiaoting Shen, C Zhou
    Abstract:

    Introduction Multiple studies have been performed to evaluate the efficiencies of various endometrial preparation protocols. However, to date, the most appropriate method of endometrial preparation for frozen-thawed embryo transfer (FET) remains debated. To our knowledge, there are no studies comparing FET cycle endometrial preparation protocol for PGT patients, and this study is the first study to compare FET cycle endometrial preparation protocols for PGT patients. Material & methods This retrospective analysis included 2398 FET cycles for 1497 preimplantation genetic testing (PGT) patients with regular menstrual cycles who underwent frozen-thawed single blastocyst transfer from January 2014 to December 2017. The patients were divided into two groups according to the method of endometrial preparation for FET: 586 cycles were natural cycles(NC), and 1812 cycles were Hormone Replacement Treatment (HRT). Reproduction-related clinical outcomes of the two groups were compared. Results The NC group showed a higher clinical pregnancy rate (54.78% vs 51.66%, P=0.188) and live birth rate (45.22% vs 43.21%, P=0.394) than did the HRT group, but these differences were not statistically significant. Moreover, endometrial thickness was significantly greater in the NC group (9.91±2.05 mm vs 8.95±1.53 mm, P Conclusion Our study shows a trend towards higher pregnancy rate and live birth rate for NC compared to HRT. Large randomized controlled trials are warranted to confirm this trend. Additionally, NC is safer than HRT, avoiding ectopic pregnancy and adverse obstetric outcomes.

Yiping Zhong - One of the best experts on this subject based on the ideXlab platform.

  • comparison of assisted natural versus Hormone Replacement Treatment cycles in 3400 frozen thawed embryo transfers after preimplantation genetic testing
    Reproductive Biomedicine Online, 2021
    Co-Authors: Dongjia Chen, Bing Cai, Shuhua Zhu, Chenhui Ding, Yali Wang, Jing Wang, Jing Guo, Jiafu Pan, Yanhong Zeng, Yiping Zhong
    Abstract:

    Abstract Research question Which of the two mainstream endometrial preparation regimens, assisted natural cycle (NC) and Hormone Replacement Treatment cycle (HRT), can help frozen-thawed embryo transfer (FET) cycles after preimplantation genetic testing (PGT) achieve better clinical outcomes? Design This retrospective analysis included 3400 frozen-thawed single blastocyst transfer cycles after PGT from January 2011 to November 2020, and involved 2332 patients with regular menstrual cycles. The decision to proceed with an assisted NC (n=827) or HRT (n=2573) before FET was reached based on a combination of patient preference and physician guidance. Clinical pregnancy rate, live birth rate, early miscarriage rate, and obstetric outcomes were compared. Results No significant difference was observed between the assisted NC and HRT groups in terms of clinical pregnancy rate (51.6% vs. 50.7%, P=0.634), live birth rate (44.0% vs. 43.4%, P=0.746), and early miscarriage rate (12.6% vs. 12.0%, P=0.707). Multivariate analysis indicated that the endometrial preparation protocol was not an independent factor for a clinical pregnancy or live birth. In the HRT group, the caesarean section rate (64.7% vs. 51.9%, P Conclusions For patients undergoing an PGT-FET cycle involving a single blastocyst transfer, using assisted NC and HRT for the endometrial preparation could lead to comparable rates of clinical pregnancy and live birth. Additionally, NC is safer than HRT in terms of avoiding pregnancy complications and adverse obstetric outcomes.

Li Yanping - One of the best experts on this subject based on the ideXlab platform.

  • oestrogen dose tapering during luteal phase does not affect clinical outcomes after Hormone Replacement Treatment frozen thawed embryo transfer cycles a retrospective analysis
    Human Reproduction, 2019
    Co-Authors: Zhao Jing, Zeng Qianling, Sun Lunquan, Liu Nenghui, Li Yanping
    Abstract:

    Study question Does oestrogen dose tapering during the luteal phase affect the clinical outcome after Hormone Replacement Treatment-frozen-thawed embryo transfer (HRT-FET) cycles? Summary answer Our results suggest that tapering oestrogen doses during the luteal phase results in similar clinical outcomes to those obtained with the traditional luteal phase support (LPS). What is known already Traditional LPS with oestrogen and progesterone is considered necessary in HRT-FET cycles. However, case reports have shown successful clinical pregnancies and live births in the absence of oestrogen administration after embryo transfers. Study design, size, duration This was a retrospective study on 6035 HRT-FET cycles extending over 7 years from January 2011 to June 2018 at the reproductive medicine centre of Xiangya Hospital. Participants/materials, setting, methods We compared the clinical outcomes of 1632 HRT-FET cycles with tapered oestrogen doses from 12 days after embryo transfer (study group) to those of 4403 HRT-FET cycles maintained on constant oestrogen doses during the luteal phase (control group) in the case of positive serum HCG test. Main results and the role of chance We found similar biochemical pregnancy rates (52.1% vs. 51.9, P = 0.864), clinical pregnancy rates (44.9% vs. 43.2%, P = 0.249), implantation rates (29.8% vs. 29.3%, P = 0.591) and miscarriage rates (16.0% vs. 14.6%, P = 0.379) between the studied groups. Limitations, reasons for caution Retrospective, design-associated biases are possible. In addition, some baseline characteristics differed between groups. Finally, we did not compare live birth rates between groups. Wider implications of the findings Our study showing similar outcomes between traditional LPS and oestrogen tapering during the luteal phase indicates that oestrogen may be cautiously tapered during the luteal phase after HRT-FET cycles. Study funding/competing interest(s) This work was supported by the National Natural Science Foundation of China (grant no. 81401269) and the class General Financial Grant from the China Postdoctoral Science Foundation (grant no. 2017M620360). The authors declare that they have no competing interests. Trial registration number N/A.

Silvia Franceschi - One of the best experts on this subject based on the ideXlab platform.

  • Hormone Replacement Treatment and breast cancer risk an age specific analysis
    Cancer Epidemiology Biomarkers & Prevention, 1997
    Co-Authors: Alessandra Tavani, Claudia Braga, C La Vecchia, Eva Negri, Silvia Franceschi
    Abstract:

    The relationship between Hormone Replacement Treatment (HRT) and breast cancer risk was considered in age-specific groups of women, combining data from two case-control studies conducted between 1983 and 1994 in six Italian centers. Cases were comprised of 5984 women, below age 75 years, with histologically confirmed breast cancer, and controls were comprised of 5504 women admitted to the hospital for a wide spectrum of acute, nonneoplastic, nonHormone-related diseases. Ever-use of HRT was reported by 6.1% of the cases and 5.5% of the controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95% confidence interval (CI), 1.0-1.4]. A significant trend in risk with duration of use was observed. Separate analysis for women or = 60 months of use. Thus, this study suggests that the relationship between HRT and breast cancer risk is influenced by age at diagnosis and that any risk-benefit assessment is particularly critical for women using HRT several years after menopause.

  • Hormone Replacement Treatment and breast cancer risk a cooperative italian study
    British Journal of Cancer, 1995
    Co-Authors: C La Vecchia, Eva Negri, Silvia Franceschi, A Favero, Oriana Nanni, Rosa Filiberti, E Conti, Maurizio Montella, A Veronesi, Monica Ferraroni
    Abstract:

    The relationship between Hormone Replacement Treatment (HRT) and breast cancer risk was analysed using data from a case-control study conducted between June 1991 and February 1994 in six Italian centres on 2569 patients aged below 75 with histologically confirmed breast cancer and 2588 controls admitted to hospital for a wide spectrum of acute, non-neoplastic, non Hormone-related diseases. Ever HRT use was reported by 7.5% of cases and 7.5% of controls, corresponding to a multivariate odds ratio (OR) of 1.2 [95% confidence interval (CI), 0.9-1.5]. The risk increased with increasing duration of use: the ORs were 1.0 for use lasting less than 1 year, 1.3 for 1-4 years and 1.5 for 5 years or more. There was no clear pattern of risk with reference to time since starting use, but the OR was significantly elevated (OR = 2.0, 95% CI 1.3-2.9) for women who had stopped HRT within the last 10 years. No association was observed in those who had stopped HRT more than 10 years ago (OR = 1.0). The increased OR for women who had stopped HRT within the last 10 years was consistent across strata of identified covariates, and was significantly related to duration of use. This study confirms the absence of a strong association between HRT and breast cancer risk, although the risk estimate was above unity for women who had used HRT for 5 years or longer. However, the risk was significantly elevated in the short to medium term after use, particularly for long-term use. This short-term increased risk is consistent with an effect of HRT on one of the later stages of the process of breast carcinogenesis. The flattening of risk with increasing time since stopping, and hence the absence of a long-term cumulative excess in breast cancer risk after stopping HRT exposure, has relevant implications on individual risk assessment and public health.